Printer Friendly

PDL MEETS MANUFACTURING MILESTONE, MAKES DRUG SUBSTANCE FOR CLINICAL TRIALS

 MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Protein Design Labs Inc. (PDL) (NASDAQ: PDLI) said today that its manufacturing facility has produced its first lots of antibody for use in clinical trials. PDL expects to file an Investigational New Drug (IND) application later this year to utilize the antibody in a Phase II trial for acute myeloid leukemia.
 Sufficient quantities of the SMART(TM) M195 Antibody were made to supply several clinical studies. Additionally, PDL has entered into an agreement to sell a portion of the production to Kanebo Ltd. of Japan, PDL's Asian licensee for SMART M195.
 The material, which was made according to federally required Good Manufacturing Practices (GMP), has been vialed and has passed necessary quality-control tests. The antibody was produced at PDL's 38,000 square-foot Minneapolis plant. Material for the completed Phase I trial was made at the Memorial Sloan-Kettering Cancer Center, where the Phase I trial was conducted.
 Protein Design Labs, founded in 1986, is developing next-generation antibodies and other novel proteins to treat various disease conditions, including viral infections, autoimmune and inflammatory diseases, cancer and cardiovascular disease.
 PDL has four potential products in clinical trials. They are a human antibody against cytomegalovirus (CMV), which is being investigated for CMV retinitis in AIDS patients and other CMV infections; a human antibody against the hepatitis B virus; the SMART(TM) Anti-Tac Antibody for graft-versus-host disease, certain leukemias and lymphomas, and organ transplant rejection; and the SMART M195 Antibody for myeloid leukemia.
 PDL believes its human and computer-designed SMART (humanized) monoclonal antibodies will have a longer half-life and will be less immunogenic than traditional mouse antibodies and therefore will be more effective as human therapeutics.
 -0- 10/4/93
 /CONTACT: Peter Dworkin, director, Corporate Communications, of Protein Design Labs, 415-903-3721/
 (PDLI)


CO: Protein Design Labs Inc. ST: California IN: MTC SU: PDT

JH-RB -- SE003 -- 8167 10/04/93 08:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 4, 1993
Words:313
Previous Article:ARABESQUE ANNOUNCES AND SHIPS ECCO SIMPLICITY AND NEW VERSION OF ECCO PROFESSIONAL; EXTENDS ECCO SUPERPIM TO ENTRY-LEVEL USERS
Next Article:PINNACLE MICRO INTRODUCES NEW SIERRA 1.3GB OPTICAL HARD DRIVE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters